Year: 2024

TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is excited to announce that it has been contracted as a supplier of its GMP LaNeo™ MDMA to a clinical trial at Mt. Sinai Health System. “We’re looking forward to supporting the team at Mt. Sinai Health System with high quality clinical trial drug product,” said Nicholas Kadysh, CEO, PharmAla Biotech. “Sinai houses some of the best researchers in the world, executes a significant amount of work for the Veterans Affairs administration (the “VA”), and has fantastic new facilities for MDMA-assisted therapy. We will work diligently to supply both...

MONTREAL, Oct. 21, 2024 (GLOBE NEWSWIRE) — In a release issued under the same headline on Monday, October 21, 2024 by NanoXplore (TSX: GRA and OTCQX: NNXPF), please note that the release date for the financial results should be Wednesday, November 6, 2024 instead of Tuesday, November 6, 2024, and that the webcast will be held on Thursday, November 7, 2024 instead of Wednesday, November 7, 2024. The corrected release follows: NanoXplore Inc. (“NanoXplore”) (TSX: GRA and OTCQX: NNXPF) is pleased to hold a webcast to discuss the results of its first quarter ended September 30th, 2024, on Thursday, November 7, 2024, at 10:00 a.m. Eastern Time. The financial results will be released on Wednesday, November 6, 2024, after the market close. Details of the Q1 Webcast   When: November 7, 2024, at 10:00 a.m. Eastern Time   Webcast: To listen...

Geneva, Switzerland, Oct. 21, 2024 (GLOBE NEWSWIRE) — SEALSQ Corp (NASDAQ: LAES) (“SEALSQ”), a company specializing in the development and sale of semiconductor Public Key Infrastructure (PKI), post-quantum technology, hardware, and software products, in collaboration with the OISTE Foundation and WISeKey, today announces that its fully integrated Root of Trust (RoT) provides one of the most complete security solutions on the market, a unique offering that covers both PKI and hardware. Using SEALSQ’s RoT solutions, businesses and organizations can trust their digital operations at every level, from cryptographic key management to device-level security. SEALSQ is one of the few players in the industry to provide such a holistic approach, integrating the entire security stack for a comprehensive solution. The term RoT...

RONKONKOMA, N.Y., Oct. 21, 2024 (GLOBE NEWSWIRE) — Pineapple Energy Inc. (Nasdaq: PEGY) (“Pineapple” or the “Company”), a leading provider of sustainable solar energy and backup power to households, businesses, municipalities, and for servicing existing systems, today announced that work will soon be commencing on two new commercial contracts for solar projects on Long Island. The work will be performed under contract for facilities within the arts & entertainment and consumer retail sectors and is expected to begin in the fourth quarter of 2024. In terms of renewable energy production, generation across the two distinct sites is expected to yield a total of 87 kW of clean energy across a total of 176 rooftop modules. “Once again, the market demonstrates that there is ample demand for commercial and industrial work in the...

NextNav’s Next-Generation 3D Terrestrial PNT Solution in Lower 900 MHz Band has Potential to Save US Economy $663 Million for One Day of a Global GPS Outage RESTON, Va., Oct. 21, 2024 (GLOBE NEWSWIRE) — NextNav Inc. (Nasdaq: NN), a leader in next-generation positioning, navigation, and timing (PNT) and 3D geolocation, announced today that its plan for a terrestrial PNT backup and complement to GPS in the Lower 900 MHz would prevent hundreds of millions of dollars in losses in the event of a global GPS outage. The Brattle Group’s economic analysis finds that a 1-day global GPS outage could cost the American economy $1.6 billion, and NextNav’s proposal could prevent a loss of $663 million to the economy for a 24-hour outage period. Adopting NextNav’s proposal to reconfigure the Lower 900 MHz band offers the US economy a $10.8 billion...

On 4 March 2024, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 13 of 1 March 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 200 million during the period 4 March 2024 to 31 December 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules).Trading day No. of shares Average price Amount    Accumulated until 11/10/2024 263,087 556.46 146,397,243    Monday, 14 October 2024 1,600 582.17 931,472    Tuesday, 15 October 2024 1,600 581.27 930,032    Wednesday, 16 October 2024 1,600 579.50 927,200    Thursday,...

Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast’s interim financial results for FY 2023/24 the company will host a conference call to present the financial results and answer questions from investors and financial analysts.A presentation will be available on Coloplast’s website approximately 1 hour before the conference call.Please note that the webcast of the conference call will be available during and after the event. Coloplast will be represented by:Kristian Villumsen – President & CEOAnders Lonning-Skovgaard – Executive Vice President, CFOAleksandra Dimovska – Vice President, Investor RelationsKristine Husted Munk – Senior Manager, Investor Relations  WebcastAny participants who do not wish to actively participate in the question & answer session,...

— IkT-001Pro to be developed as a New Molecular Entity as the first oral, potentially disease-modifying treatment for a rapidly fatal disease primarily afflicting women between the ages of 30 and 60 — BOSTON and ATLANTA, Oct. 21, 2024 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Cardiopulmonary and Neurodegenerative disease through Abelson Tyrosine Kinase inhibition, today announced the closing of a private placement of approximately $110 Million from the issuance and sale of shares of the Company’s common stock and accompanying warrants with potential aggregate financing of up to approximately $275 Million upon the full cash exercise of the warrants issued in...

Business Transformation Office Driving Strategic Initiatives to Accelerate Profitable Growth, Increase Margins and Drive Consistent Returns on Invested Capital in the Mid-to-High Teens Ad Hoc Transformation Committee of the Board to Oversee Execution of Strategic Initiatives Board of Directors Initiates Search for New Chief Financial Officer to Support the Achievement of the Company’s ROIC Goals Sheila Anderson Named to Newly Created Role of Chief Data and Analytics Officer to Lead Digital Transformation BROOKINGS, S.D., Oct. 21, 2024 (GLOBE NEWSWIRE) — Daktronics Inc (“Daktronics” or the “Company”) (Nasdaq – DAKT) today announced the next phase of its ongoing business transformation plan to accelerate profitable growth, increase profit margins, and drive returns that are consistently in the mid-to-high teens and well above...